Filtered By:
Therapy: Corticosteroid Therapy
Vaccination: Pneomococcal Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 95 results found since Jan 2013.
COVID-19 patients hospitalized after the fourth wave of the pandemic period in Vietnam: Clinical, laboratory, therapeutic features, and clinical outcomes
CONCLUSIONS: Severe and critical COVID-19 patients frequently have several comorbidities, multiple lung lesions along with a variety of clinical signs. Despite receiving antivirals, antibiotics, corticosteroids, anticoagulants, and even ECMO therapy, the patient encountered multiple complications, with a fatality rate of up to 38.27%.PMID:37574340 | DOI:10.1016/j.jfma.2023.07.020
Source: J Formos Med Assoc - August 13, 2023 Category: General Medicine Authors: Trinh Cong Dien Le Van Nam Pham Ngoc Thach Le Van Duyet Source Type: research
Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases
Int Immunopharmacol. 2023 Jun 3;120:110342. doi: 10.1016/j.intimp.2023.110342. Online ahead of print.ABSTRACTWe conducted a single-centre retrospective cohort study in a French University Hospital between 2010 and 2018 to describe the risk of severe infectious event (SIE) within 2 years after the date of first rituximab infusion (T0) prescribed after the evidence of acquired hypogammaglobulinemia (gamma globulins [GG] ≤ 6 g/L) in the setting of autoimmune diseases (AID) other than rheumatoid arthritis. SIE occurred in 26 out of 121 included patients. Two years cumulative incidence rates were 12.7 % (95 % CI 5.1-23.9) in ...
Source: International Immunopharmacology - June 5, 2023 Category: Allergy & Immunology Authors: Xavier Boumaza Margaux Lafaurie Emmanuel Treiner Ondine Walter Gregory Pugnet Guillaume Martin-Blondel Damien Biotti Jonathan Ciron Arnaud Constantin Marie Tauber Florent Puisset Guillaume Moulis Laurent Alric Yves Renaudineau Dominique Chauveau Laurent S Source Type: research
COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea: A Nationwide Multicenter Survey
CONCLUSION: These results suggest pneumonitis as a potentially significant safety concern for vaccines against SARS-CoV-2. Clinical awareness and patient education are necessary for early recognition and prompt management. Additional research is warranted to identify the epidemiology and characterize the pathophysiology of vaccine-associated pneumonitis.PMID:37038643 | PMC:PMC10086377 | DOI:10.3346/jkms.2023.38.e106
Source: J Korean Med Sci - April 11, 2023 Category: General Medicine Authors: Hongseok Yoo Song Yee Kim Moo Suk Park Sung Hwan Jeong Sung-Woo Park Hong Lyeol Lee Hyun-Kyung Lee Sei-Hoon Yang Yangjin Jegal Jung-Wan Yoo Jongmin Lee Hyung Koo Kang Sun Mi Choi Jimyung Park Young Whan Kim Jin Woo Song Joo Hun Park Won-Il Choi Hye Sook C Source Type: research
Immunity to fungi in the lung
Semin Immunol. 2023 Feb 23;66:101728. doi: 10.1016/j.smim.2023.101728. Online ahead of print.ABSTRACTThe respiratory tree maintains sterilizing immunity against human fungal pathogens. Humans inhale ubiquitous filamentous molds and geographically restricted dimorphic fungal pathogens that form small airborne conidia. In addition, pathogenic yeasts, exemplified by encapsulated Cryptococcus species, and Pneumocystis pose significant fungal threats to the lung. Classically, fungal pneumonia occurs in immune compromised individuals, specifically in patients with HIV/AIDS, in patients with hematologic malignancies, in organ tra...
Source: Seminars in Immunology - February 25, 2023 Category: Allergy & Immunology Authors: Lena J Heung Darin L Wiesner Keyi Wang Amariliz Rivera Tobias M Hohl Source Type: research
Risk of infections in patients with pemphigus treated with rituximab versus azathioprine or mycophenolate mofetil: A large-scale global cohort study
CONCLUSION: Within the first 12 months after treatment, patients under rituximab experience an elevated risk of COVID-19, parasitic and CMV infections. Rituximab is associated with pneumonia, osteomyelitis, and viral diseases even beyond the first year after therapy. Pneumococcal vaccine and suppressive antiviral therapy should be considered even one year following therapy. No signal for elevated risk of tuberculosis, hepatitis B virus reactivation, pneumocystis jiroveci pneumonia, and progressive multifocal leukoencephalopathy.PMID:36763798 | DOI:10.1093/bjd/ljac118
Source: The British Journal of Dermatology - February 10, 2023 Category: Dermatology Authors: Khalaf Kridin Noor Mruwat Kyle T Amber Ralf J Ludwig Source Type: research
